Dipropyl ether Purity 0,99
- Known as:
- Dipropyl ether Purity 0,99
- Catalog number:
- [111-43-3]
- Product Quantity:
- 5 g
- Category:
- -
- Supplier:
- VUP
- Gene target:
- Dipropyl ether Purity 99
Related genes to: Dipropyl ether Purity 0,99
- Gene:
- BST2 NIH gene
- Name:
- bone marrow stromal cell antigen 2
- Previous symbol:
- -
- Synonyms:
- CD317, tetherin
- Chromosome:
- 19p13.11
- Locus Type:
- gene with protein product
- Date approved:
- 1994-11-17
- Date modifiied:
- 2016-07-29
Related products to: Dipropyl ether Purity 0,99
(+)-N-Acetyl 3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b][1,4]oxazine-9-ol Triisopropylsilyl Ether CAS: 1034706-81-4 Formula: C23H37NO3Si(1-Methylcyclohexanyl)methyl-4-aminophenyl Ether C14H21NO CAS: 887406-96-4(1-Methylcyclohexanyl)methyl-4-aminophenyl Ether CAS: 887406-96-4 Formula: C14H21NO(1-Methylcyclohexanyl)methyl-4-nitrophenyl Ether C14H19NO3 CAS: 85002-76-2(1-Methylcyclohexanyl)methyl-4-nitrophenyl Ether CAS: 85002-76-2 Formula: C14H19NO3(2-Methoxyethyl)-methylamine Purity 0,98(2-Methoxyethyl)-methylamine Purity 0,98(2-Methoxyethyl)-methylamine Purity 0,98(2-Methoxyethyl)-methylamine Purity 0,98(2-Methoxyethyl)-methylamine Purity 0,98(2-Methoxyethyl)-methylamine Purity 0,98(2S,3R,4E)-2-Amino-4-decene-1,3-diol Ethyl Ether C12H25NO2 CAS:(2S,3R,4E)-2-Amino-4-decene-1,3-diol Ethyl Ether CAS: Formula: C12H25NO2(2S,3R,4E)-2-Amino-4-hepten-1,3-diol Ethyl Ether C9H19NO2 CAS:(2S,3R,4E)-2-Amino-4-hepten-1,3-diol Ethyl Ether CAS: Formula: C9H19NO2 Related articles to: Dipropyl ether Purity 0,99
- Pretreatment immune profiles associated with immune-related adverse events (irAEs) may inform individualized management strategies, including enhanced monitoring and early toxicity intervention, in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab. In this cohort (n = 51), we analyzed pretreatment peripheral blood parameters and whole-blood transcriptomic profiles. Higher lymphocyte and monocyte counts (odds ratios [ORs] 14.36 and 9.90, respectively) were significantly associated with an increased risk of irAEs, whereas higher neutrophil counts and C-reactive protein levels (ORs 0.08 and 0.27, respectively) were associated with a decreased risk. To characterize immune pathways associated with irAE development, we performed whole-blood transcriptomic analyses. Gene set enrichment analysis revealed upregulation of lymphocyte- and humoral immunity-related pathways and downregulation of neutrophil- and inflammatory-related pathways in patients who developed irAEs. CIBERSORTx demonstrated reduced neutrophil fractions and increased proportions of CD8⁺ T cells and activated memory CD4⁺ T cells, indicating an adaptive immune-dominant profile. Exploratory analysis identified five candidate genes (ANAPC1, CDK4, MCM6, GRAP2, and BST2) that may contribute to the immune features associated with irAE development. Collectively, these findings suggest that irAE development is associated with a distinct systemic immune profile characterized by enhanced lymphocyte-related and reduced neutrophil-related immune activity. - Source: PubMed
Publication date: 2026/04/23
Kinase SatokaNagumo YoshiyukiIsoda BunpeiSakurai HiromichiTakahashi ReoSuzuki ShuheiYamaguchi AkaneYanagihashi RyotaTanuma KozaburoNitta SatoshiShiga MasanobuKojo KosukeIkeda AtsushiKawahara TakashiHoshi AkioKandori ShuyaMathis Bryan JNishiyama Hiroyuki - We constructed a gene coexpression network to uncover central key genes related to Sjögren's disease (SjD), and investigated the clinical significance of bone marrow stromal antigen 2 (BST2) in SjD. - Source: PubMed
Publication date: 2026/04/09
Ren TianZhou XinZhou EryeLiu CuipingWu JianChang XinChen Weichang - Despite the widespread success of combination antiretroviral therapy (cART) in suppressing plasma viremia to undetectable levels, people living with HIV-1 (PLWH) continue to face a significantly elevated risk of chronic inflammation and Serious Non-AIDS Events (SNAEs). In this narrative review, we bridge the critical gap between molecular virology, immunometabolism, and clinical pathology by examining the complex interface of intrinsic immunity and viral persistence. We analyzed the evolutionary "arms race" between conserved host restriction factors, including TRIM5α, APOBEC3G, SAMHD1, BST-2, MX2, and SERINC, and the sophisticated viral evasion mechanisms that facilitate reservoir establishment. We further examined the role of bacterial translocation and gut barrier dysfunction in perpetuating systemic inflammation, emphasizing how HIV-1-mediated depletion of mucosal Th17 cells and disruption of tight junction proteins create a "leaky gut" that permits microbial product translocation despite suppressive therapy. Among viral proteins that may contribute to residual pathology during suppressive cART, we focused on the HIV-1 matrix protein p17, which has been proposed to function as a secreted "viral cytokine" from latent reservoirs, acting through CXCR1/CXCR2 receptors and the RACK1-JAK1-STAT1 pathway. Although primarily characterized in in vitro and ex vivo models, emerging data suggested that p17 may sustain systemic immune activation and metabolic reprogramming; however, its relative contribution compared with other viral proteins (Tat, Nef, gp120) in virologically suppressed patients remains to be fully delineated in human studies. Furthermore, we examined how HIV-1 hijacks cellular bioenergetics by shifting host cells from oxidative phosphorylation to aerobic glycolysis. We present an integrative model that connects restriction factor biology, p17-mediated chronic inflammation, immunometabolic dysregulation, and gut barrier dysfunction into a unified pathogenic framework, distinguishing established mechanisms from working hypotheses. Last, we assessed emerging therapeutic strategies, including CRISPR/Cas9-mediated enhancement of restriction factors, modulation of the mTOR pathway, and novel "Shock and Kill" approaches, stratified by development stage and demonstrated endpoints, offering potential pathways toward a functional cure. - Source: PubMed
Publication date: 2026/03/10
Nitsotolis ThomasAssimakopoulos Stelios FKouriannidi ElliLagadinou MariaPapalexandrou AlexiaIoannou PetrosMarangos MarkosMilionis HaralamposChristaki Eirini - Triple negative breast cancer (TNBC) poses a significant clinical challenge in imaging and therapy due to absence of conventional targets such as estrogen, progesterone, and HER2 receptors. The aim of this study is to identify potential targets for TNBC through comprehensive transcriptomic analyses and validation in TNBC cell lines and tissues. - Source: PubMed
Publication date: 2026/02/04
Lee HyunjongKim GiroKim MinaKim Jung LimJung Kyung-HoLee Kyung-Han - Senescent cells contribute to degenerative processes in multiple tissues, including the retina. In the retinal pigment epithelium (RPE), their accumulation is closely associated with retinal aging and disease progression. Eliminating senescent RPE cells has shown therapeutic potential, but conventional senolytics often lack the specificity required to spare non-senescent cells, raising safety concerns. To overcome this, we performed integrated transcriptomic analyses of male mouse-derived RPE cells under natural aging and chemically induced senescence conditions. These analyses identified Bst2 as a membrane-localized marker selectively upregulated in senescent RPE cells, with minimal expression in young controls. Based on this discovery, we developed a modular, antibody-pluggable drug delivery platform-B-Z-PON-comprising mesoporous silica nanoparticles functionalized with a recombinant Fc-binding domain and conjugated with anti-Bst2 antibodies. This nanocarrier selectively accumulates in Bst2-expressing senescent RPE cells, enabling targeted drug delivery and sparing healthy retinal cells. In vivo administration of ABT-263-loaded B-Z-PON in aged and senescence-induced retinal degeneration models resulted in the selective ablation of senescent cells, restoration of RPE function, and improved visual outcomes. Together, our study integrates senescence-specific marker discovery with precision nanomedicine, establishing a versatile platform for targeted senotherapy. These findings offer a promising therapeutic approach for retinal aging disorders, such as age-related macular degeneration. - Source: PubMed
Publication date: 2026/03/18
Oh Jun YongChae Jae-ByoungLee Hyo KyungPark Chul-WooBae MinseoKim GyuriOh YujeongYang GyeongseokKim SangpilOk Hae WonKim DohyunKim ChaekyuLee SeminJang JiwonChung HyewonRyu Ja-Hyoung